Shattuck Labs, Inc. Share Price & Technical Analysis
STTK · $6.10 (+0.16%)
Healthcare / Biotechnology
$6.10
+0.16%
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version …
Price chart
Seasonality
May has 0 positive and 4 negative years (last 5 years shown)
-14% return in May, -12% avg return in past 3 year May month.
69% return in 2026, 144% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 5% | 0% | 68% | 9% | -14% | – | – | – | – | – | – | – | 69% |
| 25 | -8% | 18% | -31% | 11% | 0% | -20% | 0% | 25% | 140% | -21% | 5% | 68% | 188% |
| 24 | 29% | -9% | -3% | 17% | -30% | -47% | 0% | -10% | -3% | -7% | -15% | 9% | -70% |
| 23 | 75% | 12% | -38% | 3% | -7% | 15% | -19% | -15% | -32% | 0% | 25% | 294% | 313% |
| 22 | -21% | -28% | -14% | -14% | -29% | 37% | -7% | -16% | -18% | 0% | -18% | 5% | -123% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$493.82M
P/E ratio
—
52W high
$8.33
52W low
$0.71
Volume
3,38,676
Beta
1.19
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Shattuck Labs, Inc. share price today?
- Shattuck Labs, Inc. (STTK) last traded around $6.10 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does STTK have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for STTK. Download the app for real-time alerts.
- How can I analyze Shattuck Labs, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.